A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
In this review, researchers discussed strategies for identifying and treating infection in patients undergoing intensive chemotherapy.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
Current transfusion recommendations do not adequately inform transfusion in patients with hematologic malignancies, who are increasingly treated as outpatients.
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
There are currently limited data to inform an optimal treatment strategy for cytokine release syndrome, a common complication of CAR T therapy.